サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426451

イブルチニブの世界市場レポート 2024

Ibrutinib Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
イブルチニブの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

イブルチニブの市場規模は、今後数年間で急激に成長すると予想されています。2028年には23.1%の年間複合成長率（CAGR）で419億8,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、潜在的なラベルの拡大、世界市場の拡大、バイオシミラーとの競合の激化、と患者中心のヘルスケアモデルの採用に起因すると考えられます。予測期間中に予想される主な動向には、適応症と臨床試験の拡大、競合情勢と市場参入のダイナミクス、バイオシミラーとジェネリック医薬品の開発、医療技術の評価、市場アクセス、現実世界の証拠と医療の利用と長期的な安全性プロファイルの確立が含まれます。

予測されるリンパ腫症例の増加により、近い将来、イブルチニブ市場の拡大が促進されると予想されます。リンパ腫は、免疫系の感染と戦う細胞であるリンパ球に由来するがんであり、免疫応答に不可欠な白血球の異常増殖によって発生します。イブルチニブは、細胞内の増殖シグナルを伝達するチロシンキナーゼ酵素を阻害することにより、リンパ腫、特にB細胞悪性腫瘍の治療に使用されます。たとえば、2022年9月の時点で、Cancer Australiaは2022年に7,397人のリンパ腫と診断された症例を報告し、オーストラリアにおけるリンパ腫による死亡者数は、2020年の1,679人に比べて1,766人に増加しました。その結果、リンパ腫の発生率の増加が、イブルチニブ市場の成長を推進する重要な要因となっています。

がんケアと治療の強化を目的とした政府の取り組みは、イブルチニブ市場の成長に貢献すると予想されます。これらの取り組みには、がん患者のアクセスしやすさ、手頃な価格、ケアの質を向上させるために政府が実施する政策、資金提供、プログラムが含まれます。画期的ながん治療法であるイブルチニブへのアクセスの強化は、補助金プログラムや調査資金を通じて促進され、最終的には患者のケアと転帰を改善します。たとえば、2023年9月現在、25年以内にがんによる死亡率を半減することを目的とした米国政府のがんムーンショット計画の復活は、疾病管理予防センター（CDC）の支援を受けています。この取り組みは、今後四半世紀にわたってがんによる死亡率を50％削減し、がん生存者とその家族に包括的な支援を提供するという野心的な目標を設定しています。その結果、がん治療と治療の改善を目的とした政府の取り組みがイブルチニブ市場の成長を推進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のイブルチニブ市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のイブルチニブ市場規模実績と成長、2018年～2023年
  • 世界のイブルチニブ市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のイブルチニブ市場、タイプ別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • カプセル
  • タブレット
  • 世界のイブルチニブ市場、流通チャネル別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のイブルチニブ市場、用途別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 慢性リンパ性白血病（CLL）
  • 小リンパ球性リンパ腫（SLL）
  • その他の用途
  • 世界のイブルチニブ市場、エンドユーザー別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 病院
  • クリニック
  • 専門センター
  • 外来手術センター

第7章 地域と国の分析

  • 世界のイブルチニブ市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 世界のイブルチニブ市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • イブルチニブ市場の競合情勢
  • イブルチニブ市場の企業プロファイル
    • Johnson And Johnson Pvt Ltd.
    • ABBVie Inc.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Fresenius Kabi Oncology Ltd.

第31章 その他の大手と革新的な企業

  • Teva Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • Cipla Limited
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Ltd.
  • Supriya Lifescience Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Accord Healthcare Limited
  • Natco Pharma Ltd.
  • Haoyuan Chemexpress
  • Toronto Research Chemicals
  • Shilpa Medicare Limited
  • ScinoPharm Taiwan Ltd.
  • Beacon Pharmaceuticals plc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13463

Ibrutinib is a small-molecule anti-cancer drug that hinders B-cell proliferation and survival by binding irreversibly to the protein Bruton's tyrosine kinase (BTK). This oral medication may require adjustments based on the patient's response and any encountered side effects.

Ibrutinib is available in two primary forms, capsules and tablets. Capsules are defined as small gelatinous cases containing medicine, often offering a more convenient ingestion method compared to tablets. These formulations are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, catering to multiple applications such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and others. The diverse settings where Ibrutinib is utilized encompass hospitals, clinics, specialty centers, and ambulatory surgical centers.

The Ibrutinib market research report is one of a series of new reports from The Business Research Company that provides Ibrutinib market statistics, including Ibrutinib industry global market size, regional shares, competitors with an Ibrutinib market share, detailed Ibrutinib market segments, market trends and opportunities, and any further data you may need to thrive in the Ibrutinib industry. This Ibrutinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ibrutinib market size has grown exponentially in recent years. It will grow from $14.87 billion in 2023 to $18.29 billion in 2024 at a compound annual growth rate (CAGR) of 23.0%. The growth observed during the historical period can be credited to FDA approval and regulatory milestones, success in clinical trials, a heightened understanding of the B-cell receptor pathway, expanded indications, and increased adoption by physicians.

The ibrutinib market size is expected to see exponential growth in the next few years. It will grow to $41.98 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The anticipated growth in the forecast period can be attributed to potential label expansions, the expansion of the global market, increased competition from biosimilars, and the adoption of patient-centric healthcare models. Major trends expected during the forecast period encompass expanded indications and clinical trials, the dynamics of the competitive landscape and market entry, development in biosimilars and generics, health technology assessment, and market access, as well as the utilization of real-world evidence and the establishment of long-term safety profiles.

The projected rise in lymphoma cases is anticipated to drive the expansion of the ibrutinib market in the foreseeable future. Lymphoma, a cancer originating from lymphocytes, the immune system's infection-fighting cells, occurs when there is abnormal growth in these white blood cells crucial for the immune response. Ibrutinib is employed in treating lymphoma, specifically B-cell malignancies, by inhibiting tyrosine kinase enzymes that transmit growth signals in cells. For example, as of September 2022, Cancer Australia reported 7,397 diagnosed lymphoma cases in 2022, with the number of deaths from lymphoma in Australia increasing to 1,766, compared to 1,679 deaths in 2020. Consequently, the escalating incidence of lymphoma is a key factor propelling the growth of the ibrutinib market.

Government initiatives aimed at enhancing cancer care and treatment are expected to contribute to the growth of the ibrutinib market. These initiatives encompass policies, funding, and programs implemented by governments to improve the accessibility, affordability, and quality of care for cancer patients. Enhanced access to Ibrutinib, a groundbreaking cancer treatment, is facilitated through subsidized programs and research funding, ultimately improving patient care and outcomes. For instance, as of September 2023, the US government's revival of the Cancer Moonshot initiative, dedicated to halving the cancer death rate within 25 years, is supported by the Centers for Disease Control and Prevention (CDC). The initiative sets ambitious goals to reduce the cancer death rate by 50% over the next quarter century and provide comprehensive support to cancer survivors and their families. Consequently, government initiatives aimed at improving cancer care and treatment are propelling the growth of the ibrutinib market.

Health side effects pose a significant challenge, limiting the growth of the ibrutinib market during the forecast period. These unintended and often undesirable outcomes or symptoms resulting from ibrutinib use can hinder market growth by reducing patient compliance, raising medical concerns, damaging reputation, prompting regulatory scrutiny, fostering competition from alternative treatments, increasing research and development costs, necessitating patient education and support, and overall affecting market dynamics. For instance, according to Mayo Clinic, some side effects of ibrutinib include fever, nausea, confusion, and body pain. Therefore, the health side effects associated with ibrutinib are hindering the growth of the ibrutinib market.

Leading companies in the ibrutinib market are actively developing innovative drugs such as Imbruvica to better serve patients and gaining approvals. Imbruvica (ibrutinib), a kinase inhibitor used to treat pediatric patients with chronic graft-versus-host disease (cGVHD) after systemic therapy failures, received US Food and Drug Administration (FDA) approval in August 2022. Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, developed Imbruvica as a once-daily oral medication that blocks the BTK protein involved in cGVHD development, providing a significant advancement in treatment options.

In November 2021, ArchiMed SAS, a France-based investment firm specializing in the healthcare industry, acquired majority stakes from Suan Farma S.A.U. for an undisclosed amount. This strategic acquisition aims to expand ArchiMed SAS's presence in the pharmaceutical industry in Spain and Portugal, leverage Suan Farma's manufacturing capabilities, and access its extensive product portfolio. Suan Farma S.A.U., a Spain-based pharmaceutical company, is currently in the development phase of Ibrutinib drugs for cancer treatments.

Major companies operating in the ibrutinib market report are Johnson And Johnson Pvt Ltd., ABBVie Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi Oncology Ltd., Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Apotex Inc., Cipla Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Supriya Lifescience Ltd., Incepta Pharmaceuticals Ltd., Accord Healthcare Limited, Natco Pharma Ltd., Haoyuan Chemexpress, Toronto Research Chemicals, Shilpa Medicare Limited, ScinoPharm Taiwan Ltd., Beacon Pharmaceuticals plc, Minakem SAS, Wisdom Pharmaceutical Co Ltd., Bluepharma Group, Clearsynth Labs Limited, LGM Pharma LLC, MSN Laboratories Pvt Ltd., Bulat Pharmaceutical Private Limited, A.R. Life Science Pvt. Ltd., Hetero Drugs Ltd., Anant Pharmaceuticals Pvt. Ltd.

North America was the largest region in the ibrutinib market in 2023. The regions covered in the ibrutinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ibrutinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The ibrutinib market consists of sales of Imbruvica. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ibrutinib Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ibrutinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ibrutinib? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ibrutinib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Capsules; Tablets
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 3) By Applications: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Other Applications
  • 4) By End-User: Hospitals; Clinics; Specialty Centers; Ambulatory Surgical Centers
  • Companies Mentioned: Johnson And Johnson Pvt Ltd.; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; Fresenius Kabi Oncology Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ibrutinib Market Characteristics

3. Ibrutinib Market Trends And Strategies

4. Ibrutinib Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Ibrutinib Market Size and Growth

  • 5.1. Global Ibrutinib Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Ibrutinib Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Ibrutinib Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ibrutinib Market Segmentation

  • 6.1. Global Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Capsules
  • Tablets
  • 6.2. Global Ibrutinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.3. Global Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Other Applications
  • 6.4. Global Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Specialty Centers
  • Ambulatory Surgical Centers

7. Ibrutinib Market Regional And Country Analysis

  • 7.1. Global Ibrutinib Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Ibrutinib Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ibrutinib Market

  • 8.1. Asia-Pacific Ibrutinib Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ibrutinib Market

  • 9.1. China Ibrutinib Market Overview
  • 9.2. China Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ibrutinib Market

  • 10.1. India Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ibrutinib Market

  • 11.1. Japan Ibrutinib Market Overview
  • 11.2. Japan Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ibrutinib Market

  • 12.1. Australia Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ibrutinib Market

  • 13.1. Indonesia Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ibrutinib Market

  • 14.1. South Korea Ibrutinib Market Overview
  • 14.2. South Korea Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ibrutinib Market

  • 15.1. Western Europe Ibrutinib Market Overview
  • 15.2. Western Europe Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ibrutinib Market

  • 16.1. UK Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ibrutinib Market

  • 17.1. Germany Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ibrutinib Market

  • 18.5. France Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ibrutinib Market

  • 19.9. Italy Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ibrutinib Market

  • 20.13. Spain Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ibrutinib Market

  • 21.1. Eastern Europe Ibrutinib Market Overview
  • 21.2. Eastern Europe Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ibrutinib Market

  • 22.1. Russia Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ibrutinib Market

  • 23.1. North America Ibrutinib Market Overview
  • 23.2. North America Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ibrutinib Market

  • 24.1. USA Ibrutinib Market Overview
  • 24.2. USA Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ibrutinib Market

  • 25.1. Canada Ibrutinib Market Overview
  • 25.2. Canada Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ibrutinib Market

  • 26.1. South America Ibrutinib Market Overview
  • 26.2. South America Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ibrutinib Market

  • 27.1. Brazil Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ibrutinib Market

  • 28.1. Middle East Ibrutinib Market Overview
  • 28.2. Middle East Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ibrutinib Market

  • 29.1. Africa Ibrutinib Market Overview
  • 29.2. Africa Ibrutinib Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Ibrutinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Ibrutinib Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ibrutinib Market Competitive Landscape And Company Profiles

  • 30.1. Ibrutinib Market Competitive Landscape
  • 30.2. Ibrutinib Market Company Profiles
    • 30.2.1. Johnson And Johnson Pvt Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. ABBVie Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol-Myers Squibb Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Fresenius Kabi Oncology Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Ibrutinib Market Other Major And Innovative Companies

  • 31.1. Teva Pharmaceutical Industries Limited
  • 31.2. Dr. Reddy's Laboratories Ltd.
  • 31.3. Apotex Inc.
  • 31.4. Cipla Limited
  • 31.5. Zydus Lifesciences Limited
  • 31.6. Sun Pharmaceutical Industries Ltd.
  • 31.7. Supriya Lifescience Ltd.
  • 31.8. Incepta Pharmaceuticals Ltd.
  • 31.9. Accord Healthcare Limited
  • 31.10. Natco Pharma Ltd.
  • 31.11. Haoyuan Chemexpress
  • 31.12. Toronto Research Chemicals
  • 31.13. Shilpa Medicare Limited
  • 31.14. ScinoPharm Taiwan Ltd.
  • 31.15. Beacon Pharmaceuticals plc

32. Global Ibrutinib Market Competitive Benchmarking

33. Global Ibrutinib Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ibrutinib Market

35. Ibrutinib Market Future Outlook and Potential Analysis

  • 35.1 Ibrutinib Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Ibrutinib Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Ibrutinib Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer